Posted by Michael Wonder on 30 Mar 2021
U.S. FDA accepts AbbVie's new drug application for atogepant for the preventive treatment of migraine
30 March 2021 - If approved, atogepant will be the first and only oral CGRP receptor antagonist specifically developed for the preventive treatment of migraine.
AbbVie today announced that the U.S. FDA has accepted its new drug application for atogepant, an investigational orally administered calcitonin gene-related peptide receptor antagonist (gepant), for the preventive treatment of migraine in adults who meet criteria for episodic migraine.
AbbVie anticipates a regulatory decision in late Q3 2021.
